Home | Newsletter | Store | FAQs | About | In The News | Contact
 

IPO Profile

Cytokinetics Inc.
280 East Grand Avenue, South San Francisco, California 94080
Tel: 650-624-3000
Web: www.cytokinetics.com
Ticker: CYTK
Stock Exchange: Nasdaq
Shares Issued: 6,900,000.00
Price Offered: $13.00
Amount Raised: $89,700,000.00

Underwriters:
Goldman Sachs & Co.
CS First Boston
Pacific Growth Equities
Lazard Freres


Company Description:
We are the leading biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that specifically target the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. A number of commonly used drugs and a growing body of research validate the role that the cytoskeleton plays in a wide array of human diseases. Our focus on the cytoskeleton enables us to develop novel and potentially safer and more effective classes of drugs directed at treatments for cancer, cardiovascular disease, fungal diseases and other diseases. We have developed a cell biology driven approach and proprietary technologies to evaluate the function of many interacting proteins in the complex environment of the intact human cell. We believe that our approach enhances the speed, efficiency and yield of our drug discovery and development process by accurately and rapidly identifying drug candidates with attractive properties. Our approach has yielded two drug candidates for the treatment of cancer, potential drug candidates for the treatment of congestive heart failure, and more than ten other research programs. Our most advanced drug candidate, SB-715992, is the subject of a broad Phase II clinical trials program designed to evaluate its effectiveness in many different types of cancer. An investigational new drug application, or IND, was filed with the U.S. Food and Drug Administration, or FDA, in 2003 for our second cancer drug candidate, SB-743921, which we expect will enter Phase I clinical development in early 2004. In addition, we expect to initiate Phase I clinical development for a drug candidate for the treatment of acute congestive heart failure in the second half of 2004.

 
Copyright 2004 CurrentOfferings